Glenmark Pharma's Q1 financials show mixed results, with some positive aspects and areas of concern

Glenmark Pharmaceuticals, a largecap company in the pharma industry, recently declared its financial results for the quarter ending June 2024. According to MarketsMOJO, a leading stock analysis platform, the stock call for Glenmark Pharma is 'Hold'. The company's financial performance for the quarter has remained flat, with a slight improvement in its score from -22 to -4 in the last three months. However, there are some positive aspects to the financials. The Profit Before Tax (PBT) has shown a significant growth of 288.2% at Rs 180.07 crore, compared to the average PBT of the previous four quarters at Rs 46.38 crore. This indicates a positive trend in the near term. Glenmark Pharma also has a strong cash position, with cash and cash equivalents at Rs 1,659.46 crore in the last six half yearly periods. The company has also been reducing its debt, with a debt-equity ratio of 0.16 times in the last five half yearly periods. Additionally, the company has been able to settle its debtors faster, with a debtors turnover ratio of 6.44 times in the last five half yearly periods. However, there are some areas of concern in the financials. The Profit After Tax (PAT) for the quarter has fallen by -1842.4% at Rs -1,218.28 crore, compared to the average PAT of the previous four quarters at Rs 69.92 crore. This indicates a negative trend in the near term. The company's interest cost has also increased by 10.59% (QoQ), which signifies increased borrowings. Moreover, the company's income from non-business activities is high, at 81.11% of the PBT, which may not be a sustainable business model. The company's earnings per share (EPS) for the quarter are at its lowest in the last five quarters at Rs -43.17, indicating a decline in profitability and lower earnings for shareholders. Additionally, the company's non-operating income for the quarter is at its highest in the last five quarters at Rs 773.17 crore, which may not be sustainable. Overall, Glenmark Pharmaceuticals has shown a mixed financial performance for the quarter ending June 2024. While there are some positive aspects, there are also areas of concern that investors should keep in mind while making investment decisions.